The Checkpoint Disease Landscape: Exploring the Top Cancer Indications

The immune checkpoint landscape has witnessed a remarkable expansion, spanning a variety of therapeutic classes like bispecific antibodies, oncolytic viruses, and ADCs pushing the boundaries of cancer immunotherapy.

Our in-depth exploration of the checkpoint disease landscape centers on the top five oncology indications, shedding light on both drug developments and clinical trials. Witness PD-1 taking the lead with 215 assets across various development stages, meet the trailblazing developers, and discover the latest data surrounding combination trials.

Top Checkpoint Disease Cancer Indiciations Report

This report, curated by our Beacon Checkpoint experts, delves into both the drug and trial landscapes and spotlights the top five oncology indications. Inside these domains, you’ll uncover:

  • A round-up of the top ten targets being studied
  • An overview of the leading developers in both the clinical and preclinical settings and
  • their assets
  • An analysis of the progression of checkpoint trials over time and their phase distribution
  • Insights into routes of administration, mechanisms of action, combination trials, and more!

You May Also Be Interested In…

What is Beacon?

Beacon is a world leading data analysis tool for preclinical and clinical trial information. With unrivalled granularity of search function, data quality, and exhaustiveness, Beacon provides timely information and gives you confidence to progress your targeted drug therapies to patients.

Learn more about how our clinical trials and drug database solutions can be tailored to your research requirements

Find out more

Menu
Search Icon
Close Icon
Search